Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H Apr 24, 2023
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol Apr 17, 2023
Checkpoint Therapeutics Announces $6.1 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Mar 31, 2023
Checkpoint Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights Mar 30, 2023
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights Mar 30, 2023
Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights Mar 29, 2023
